Alnylam Pharmaceuticals (ALNY -3.4%) dips after MLV cut the shares to Hold from Buy. The firm says it prefers to take a cautious stance ahead of pending details of disease-modifying data from its lead partnered programs. One such program is its strategic alliance with The Medicines Co. (MDCO -3%) to develop ALN-PCS, an RNAi therapeutic program for the treatment of hypercholesterolemia.
Are you Bullish or Bearish on ?
Sentiment on ()
Thanks for sharing your thoughts.